Several other therapies targeting pathways in the liver are in development, including agonists for FGF21, FXR, PPAR pathways, as well as components of the inflammatory and fibrogenesis pathways.31In addition, Nutrient Stimulated Hormone-based therapies, including the GLP-1 receptor agonist semaglutide, GLP-1/GIP dual agonist, tirzepatide, GLP1RA/GIP/GRA triple agonist, retatrutide, are showing some efficacy for MASLD/MASH and are in advanced stages of development. Here, GIP is linked to metabolic dysfunction-associated steatotic liver disease.